Skip to main content
Premium Trial:

Request an Annual Quote

Applera Will Pay Undisclosed Sum to Genetic Technologies to Settle IP-Infringement Suit

NEW YORK, Dec. 12 (GenomeWeb News) - Applera has agreed to pay Genetic Technologies an undisclosed amount to settle their ongoing patent-infringement suit surrounding the firm's junk DNA gene-testing technologies, according to Genetic Technologies.

 

While details of the 18-hour mediation session that resulted in the settlement remain confidential, the companies executed several binding agreements, including a final settlement agreement, a license agreement, and a supply agreement, according to an announcement made to Gene Technologies shareholders today. All claims and counterclaims will be dismissed, the firm said.

 

The technologies on which the case was built represents the only US patent on the use of non-coding DNA markers for gene testing.

 

Genetic Technologies originally sued Applera and two other US companies in March 2003 for not purchasing licenses and paying royalties. The other companies settled separately in November 2004. Applera agreed to pursue further negotiations on Oct. 13 and both sides agreed to a settlement on Dec. 9.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.